Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel, Ami B; O'Hare, Thomas; Deininger, Michael W

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Patel, Ami B; O'Hare, Thomas; Deininger, Michael W.

Affiliation

Patel AB; Department of Hematology and Oncology, Huntsman Cancer Institute, 2000 Circle of Hope Drive, The University of Utah, Salt Lake City, UT 84112, USA.
O'Hare T; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA.
Deininger MW; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. Electronic address: Michael.deininger@hci.utah.edu.

Hematol Oncol Clin North Am ; 31(4): 589-612, 2017 08.

Article in En | MEDLINE | ID: mdl-28673390

Subject(s)

Antineoplastic Agents/therapeutic use; Drug Discovery; Drug Resistance, Neoplasm/genetics; Fusion Proteins, bcr-abl/genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics; Protein Kinase Inhibitors/therapeutic use; Antineoplastic Agents/chemistry; Antineoplastic Agents/pharmacology; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Biological Availability; Biomarkers; Cell Survival/drug effects; Cell Survival/genetics; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl/antagonists & inhibitors; Fusion Proteins, bcr-abl/chemistry; Gene Expression Regulation, Leukemic/drug effects; Humans; Immunotherapy; Models, Molecular; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors/chemistry; Protein Kinase Inhibitors/pharmacology; Signal Transduction/drug effects; Structure-Activity Relationship

Key words

BCR-ABL1; Chronic myeloid leukemia (CML); Drug resistance; Mutation; Treatment-free remission (TFR); Tyrosine kinase inhibitor (TKI)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Fusion Proteins, bcr-abl / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Drug Discovery / Antineoplastic Agents Limits: Humans Language: En Journal: Hematol Oncol Clin North Am Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2017 Document type: Article Affiliation country: United States Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google